Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4775302

O=C(Nc1ccc2c(c1)CCN(C1CCC1)CC2)c1ccc2snnc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
NPC1 O15118 7/20 0.48
RAB9A P51151 6/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
TP53 P04637 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
SLC2A1 P11166 1/20 0.48
POLB P06746 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MLLT1 Q03111 1/20 0.46
ACKR3 P25106 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775503 0.94 MAPT (0.54) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4772603 0.85 SLC2A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4770904 0.83 RAB9A (0.52) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4775692 0.82 RAB9A (0.52) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4774281 0.82 SLC2A1 (0.58) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4767916 0.81 TMPRSS2 (0.55) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4767186 0.80 MAPT (0.46) MAPTRAB9ATP53MEN1KMT2A
Trifluoroacetic Acid SCHEMBL4770823 0.80 SLC2A1 (0.47) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4765505 0.79 SLC2A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2TP53
Trifluoroacetic Acid SCHEMBL4775284 0.79 NPC1 (0.52) MAPTNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP claimed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US claimed
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 MAPT 405/4885NPC1 2009/4885RAB9A 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.